Core Insights - Journey Medical achieved a significant milestone in 2025 with the commercial launch of EMROSI, an oral treatment for rosacea, and reported improved profitability metrics as the product gains traction [5][6] Product Performance - EMROSI generated approximately $14.7 million in net sales during the three quarters it was available in 2025, with around 53,000 total prescriptions written [4][8] - The refill behavior for EMROSI improved, with a ratio of 1.4 refills per new prescription by the end of 2025, indicating strong ongoing demand [1][8] - The company ended 2025 with over 3,500 unique dermatology prescribers for EMROSI, surpassing its initial goal [2] Financial Results - Full-year 2025 revenue rose to $61.9 million, a 10% increase from $56.1 million in 2024, driven by the launch of EMROSI [6][17] - The gross margin for 2025 was reported at 66.2%, up from 62.8% in 2024, attributed to a favorable product mix and lower inventory costs [21] - The GAAP net loss narrowed to $11.4 million in 2025, compared to a loss of $14.7 million in 2024, reflecting improved financial performance [21] Market Access and Coverage - Journey Medical reported access to approximately 100 million commercial covered lives, with contracts with two of the top three U.S. group purchasing organizations (GPOs) [7][11] - The company expects to contract with the third major GPO by early second quarter of 2026, which is anticipated to enhance market access [11] Future Outlook - The company anticipates remaining adjusted EBITDA positive in 2026, supported by expected sales growth and the leverage of its commercial organization [20] - Journey plans to launch one to two additional dermatology products later in 2026, indicating a focus on portfolio expansion [21][22] - Management expects gradual improvement in gross-to-net dynamics as formulary milestones are reached throughout 2026 [12][20]